Cholangiocarcinoma PDX Models

Identifying robust preclinical models for cholangiocarcinoma is essential for the development of targeted therapies. Patient-derived xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity. The CrownBio cholangiocarcinoma PDX collection consists of several models which provide an accurate approach to predicting an agents efficacy prior to entering the clinic. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBERCANCER SUBTYPE # per page
CC0449 ECCCLICK TO VIEW
CC11307 ADCCLICK TO VIEW
CC1470 ICCCLICK TO VIEW
CC6204 ICCCLICK TO VIEW
CC6205 ICCCLICK TO VIEW
CC6216 NACLICK TO VIEW
CC6279 ICCCLICK TO VIEW
CC6600 ICCCLICK TO VIEW
CC6604 ICCCLICK TO VIEW
CC6607 ICCCLICK TO VIEW
CC6609 ICCCLICK TO VIEW
CC6625 ICCCLICK TO VIEW
CC6637 ICCCLICK TO VIEW
CC6638 ICCCLICK TO VIEW
CC6639 ICCCLICK TO VIEW
CC6644 AdenocarcinomaCLICK TO VIEW
CC6645 ICCCLICK TO VIEW
CC6658 ICCCLICK TO VIEW
CC6679 ADCCLICK TO VIEW
CC6690 ADCCLICK TO VIEW